Abstract. To evaluate a possible role for endogenous opiates in modulating sympathetic-adrenal function in humans, we measured plasma epinephrine and norepinephrine (radioenzymatic method), blood pressure and heart rate in 8 normal men (aged 24\p=n-\33 years) before and after placebo or different doses (0.4, 4.8, 10 mg) of naloxone. In 6 subjects plasma insulin and glucagon levels were also measured by radioimmunoassay after placebo and 10 mg naloxone. Naloxone had no significant effect upon blood pressure, heart rate, plasma insulin, glucagon or norepinephrine. Placebo, 0.4 and 4.8 mg naloxone caused no significant change in peripheral levels of epinephrine while 10 mg produced an increase in epinephrine concentrations 15 min after iv injection (186 \ m=+-\23 vs 99 \ m=+-\ 9 pmol/l, P < 0.01).
Since naloxone did not modify plasma levels of insulin and glucagon, an indirect effect of naloxone on adrenal medullary secretion seems to be excluded.
These results are in agreement with in vitro experimental data obtained in animals and suggest that endogenous opiates also have a role in modulating adrenal medullary secretion in man.
Various reports indicate that opiate peptides are present not only in brain structures (Hughes et al. 1975; Smith et al. 1976; Yang et al. 1977 ) but also in peripheral tissues (Hughes et al. 1977; Schultz¬ berg et al. 1978 ; Di Giulio et al. 1980 ) such as the adrenal medulla and sympathetic ganglia. The physiological role(s) of opiate peptides in these structures is still uncertain but some authors suggest that opiates may act as modulators of sympa¬ thetic-adrenal activity.
In vivo experiments using morphine administra¬ tion have led to controversial results (Taborsky et al. 1981) . Morphine has been shown to increase, decrease or not affect plasma catecholamines (CA) in dogs, depending on the dose and on the experi¬ mental conditions. Similarly, in patients suffering acute myocardial infarction, morphine administra¬ tion has been reported to cause an increase, de¬ crease or no change in blood pressure (BP) or heart rate (HR) (Gould et al. 1978 ).
In contrast, in vitro experiments are less contro¬ versial. Konishi et al. (1979) reported that enkephalins inhibit cholinergic transmission in the sym¬ pathetic ganglia of guinea pigs and Kumakura et al. (1980) The time course of the experiment was based on the observation that in a phaeochromocytoma patient nalox¬ one administration caused an elevation of CA levels 10-15 min after injection (Mannelli et al. 1983 ).
Samples for CA measurement were drawn in vacutainers containing 100 µ of a solution with glutathione (60 mg/ml) and EGTA (90 mg/ml). put immediately in an ice-water bath and centrifuged at 4°C. Plasma samples were stored at -70°C until assayed.
Plasma samples for glucagon measurement were drawn in cold tubes containing 1000 IU Trasylol™ and 2 mg EDTA-Na2/ml blood, were centrifuged at 4°C and stored frozen until assayed.
All specimens (control and experimental samples) were measured in duplicate in the same assay.
Plasma CA were assayed by a radioenzymatic method previously described (Neri Serneri et al. 1981 Mean (± sem) insulin (µ /ml) and glucagon (pg/ml) plasma levels in 6 subjects after placebo or 10 mg naloxone. Insulin and glucagon circulating levels were also unchanged after placebo or 10 mg naloxone. These results are reported in Table 2 .
Mean (± SEM) E plasma levels are shown in Fig. 1 and Estilo & Cottrell (1982) and is in agree¬ ment with our data.
To our knowledge no data exist on the effects of higher doses of naloxone on E plasma levels in adult man.
In our study 10 mg naloxone was able to increase significantly E peripheral concentrations (Fig. 1) . The increase was slight and unable to modify BP and HR but significant (P < 0.01) and was observed in each subject studied.
It is worth mentioning that in a 31 year old patient affected by hypertensive crises due to bila¬ teral phaeochromocytoma (surgically removed) iv administration was able, on two separate occasions, to induce an increase in BP and CA plasma levels, while 0.4 mg naloxone was as ineffective as placebo administration (Mannelli et al. 1983 ).
These results, taken together, seem to support the hypothesis of an opioid inhibitory role for CA release from the adrenal medulla in man and are in agreement with other experimental data obtained in vitro (Kumakura et al. 1980) 
